Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.81 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.59 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6591133 | 0.95 | SLC18A3 (0.78) | SLC18A3SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL7388033 | 0.93 | SLC18A3 (0.76) | SLC18A3SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL7281715 | 0.89 | SLC18A3 (1.00) | SLC18A3SIGMAR1MEN1TP53CYP1A2 | |
| Hydrochloric Acid SCHEMBL7259165 | 0.87 | SIGMAR1 (0.75) | SLC18A3SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL6998658 | 0.83 | DRD2 (0.59) | SLC18A3SIGMAR1DRD2 | |
| SCHEMBL6198442 | 0.83 | SIGMAR1 (0.69) | SLC18A3SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL152587 | 0.83 | DRD2 (0.81) | SLC18A3SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL3458641 | 0.83 | SIGMAR1 (0.69) | SLC18A3SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL2554214 | 0.83 | SIGMAR1 (0.69) | SLC18A3SIGMAR1MEN1TP53CYP1A2 | |
| SCHEMBL7382464 | 0.83 | SIGMAR1 (0.69) | SLC18A3SIGMAR1MEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5644059-A | REACTION OF KETONE WITH ACRYLAMIDE AND AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-07-01 | — | — | US | claimed |
| EP-0488345-A1 | 1,4-Dihydropyridine derivatives and methods of producing the same | FUJIREBIO INC. (JP) | 1992-06-03 | — | — | EP | claimed |
| US-6608086-B2 | Selective adrenergic receptor alpha 1C antagonists without significant calcium channel activity; treating benign prostatic hyperplasia, intraocular pressure and inhibiting cholesterol synthesis | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| US-6310076-B1 | TREATING BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, TREATING DISEASES MEDIATED BY ALPHA-1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-30 | — | — | US | disclosed |
| US-6211198-B1 | BENIGN PROSTATE HYPERPLASIA; INTRAOCULAR PRESSURE; HYPOTENSIVE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-5859244-A | EXHIBIT VASODILATING ACTIVITY BASED ON CALCIUM ANTAGONISM AND PLATELET-ACTIVATING FACTOR ANTAGONISM | FUJIREBIO, INC. (JP) | 1999-01-12 | — | — | US | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-5763614-A | VASODILATION BASED ON CALCIUM ANTAGONISM AND PAF ANTAGONISM | FUJIREBIO INC. (JP) | 1998-06-09 | — | — | US | disclosed |
| US-5696268-A | REACTING N-ACYLAMINO ACID DERIVATIVE WITH OPTICALLY ACTIVE ENAMINE DERIVATIVE, REACTING PRODUCT WITH AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-12-09 | — | — | US | disclosed |
| US-5644059-A | REACTION OF KETONE WITH ACRYLAMIDE AND AMMONIA OR AMMONIUM SALT | FUJIREBIO INC. (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5367081-A | Vasodilator, antiallergen | FUJIREBIO INC. (JP) | 1994-11-22 | — | — | US | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5276150-A | Vasodilators, anticoagulants, calcium channel blockers | FUJIREBIO INC. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0488345-A1 | 1,4-Dihydropyridine derivatives and methods of producing the same | FUJIREBIO INC. (JP) | 1992-06-03 | — | — | EP | disclosed |
| EP-0400660-A1 | 1,4-dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | SLC18A3 2857/4885SIGMAR1 1194/4885MEN1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.